<DOC>
	<DOCNO>NCT02330276</DOCNO>
	<brief_summary>Early Phase Pre-Clinical Initial Clinical Research ( + ) - Epicatechin .</brief_summary>
	<brief_title>Early Phase Pre-Clinical Initial Clinical Research Epicatechin</brief_title>
	<detailed_description>This project double-blinded randomized Phase I study include dose-ranging one day PK pharmacodynamic ( PD ) study . Subjects include healthy individual subject meet American Diabetes Association ( ADA ) criteria pre-diabetes , include IFG .</detailed_description>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Healthy prediabetic base medical history Male female Must 21 75 year age ( inclusive ) Able give inform consent procedure If female , must either postmenopausal test negative pregnancy screen day procedure . Women estrogen therapy include . If childbearing potential , must practice willing continue practice appropriate birth control entire duration study Medication use stable 4 week Body Mass Index ( BMI ) &gt; 27 kg/m2 Definition prediabetes : impaired fasting glucose ( IFG , fast glucose = 100125 mg/dL ) elevate HbA1c ( 5.76.4 % ) , absence risk factor diabetes Type 2 diabetes Pregnancy Younger 21 old 75 year age Clinically significant abnormality liver kidney function ( &gt; 3x ULN ) , determine last 6 month certify clinical laboratory Recent MI stroke ( within 6 month screen ) Blood pressure ( BP ) &gt; 160 mmHg Systolic &gt; 100 mmHg Diastolic Medications thiazolidinediones , steroid , antidepressant , weight loss drug Other disease , besides type 2 diabetes , influence carbohydrate metabolism</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>